2013 Annual Meeting of the American Association for the Study of Liver Diseases*

November 1-5, 2013; Washington, DC
CCO is the official provider of online conference coverage of The Liver Meeting 2013, through Capsule Summaries, expert faculty analysis of the most important data, and downloadable slides

Highlights From AASLD 2013: HCV Investigational Agents


Extension of once-daily oral sofosbuvir plus RBV regimen to 24 weeks for patients with genotype 3 HCV produced high SVR rates comparable to those observed with 12-week regimen in genotype 2, except in treatment-experienced patients with cirrhosis.

Released: November 5, 2013

Faldaprevir triple therapy associated with 72% to 73% SVR12 rate in treatment-naive patients with genotype 1 HCV after adjusting for trial, race, and genotype 1 subtype.

Released: November 4, 2013

Interim virologic response rates appeared higher in patients treated for 24 weeks vs 12 weeks and were independent of previous treatment status, the presence of cirrhosis, or other prognostic factors.

Released: November 6, 2013

In phase IIb trial, triple-therapy regimen for 16 weeks resulted in SVR12 rate of 95% in patients infected with genotype 1b HCV, but only 17% in patients with genotype 1a HCV and IL28B CC genotype.

Released: November 8, 2013

In a phase III study, SVR24 rates were 87.4% in IFN-intolerant/ineligible patients and 80.5% in previous nonresponders and the regimen was well tolerated with few discontinuations or serious adverse events.

Released: November 11, 2013

In phase II study, 95% to 100% of treatment-naive patients achieved SVR with 8 weeks comparable to 12 weeks, and 95% to 100% of previous PI failures achieved SVR with 12-week therapy regardless of the presence of cirrhosis.

Released: November 11, 2013

12-week triple-drug regimens produced 100% SVR in treatment-experienced patients, but 6-week regimen inferior to previous 8-week and 12-week durations in treatment-naive patients.

Released: November 7, 2013

In a phase II trial, dual-therapy achieved ≥ 90% SVR12 rates in genotype 1b patients regardless of previous treatment experience and was well tolerated with no treatment-related discontinuations.

Released: November 8, 2013

In pilot study, high SVR12 response rates observed regardless of HCV subtype or inclusion of ribavirin.

Released: November 4, 2013

Expansion of the AI443-014 phase II trial demonstrated that the all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 produced SVR12 rates in > 90% of patients while being generally well tolerated.

Released: November 5, 2013

In a small, ongoing phase II study, 81% of patients achieved undetectable HCV RNA by Week 4, and 100% of evaluable patients had SVR4.

Released: November 5, 2013

In phase IIa study, simeprevir plus sofosbuvir regimens achieved high virologic response rates regardless of treatment duration or inclusion of RBV and were generally well tolerated.

Released: November 11, 2013

In phase II trial, overall SVR12 rate of 89%, with a toxicity profile consistent with pegIFN/RBV alone, and low rates of discontinuation.

Released: November 8, 2013

Sofosbuvir/ledipasvir for 12 weeks associated with 100% SVR12 rate, whereas coadministration of a third DAA yielded 90% to 100% SVR4 rates with only 6 weeks of therapy.

Released: November 7, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Gilead Sciences
Janssen Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?